Clinical trial
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
NCT01718899 is registered in ClinicalTrials.gov with OncoPep, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
- Lead sponsor
- OncoPep, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- September 30, 2016
- Enrollment
- 22 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.